Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Jazz Pharmaceuticals (JAZZ) PT Raised to $199 at BMO Capital
February 28, 2018 6:59 AM ESTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $199.00 (from $196.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 4Q revenue of $436mm vs. BMO/consensus of $438mm/442mm and adj. EPS of $2.95 vs. BMO/consensus of... More
Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 6c; Guides FY18 Relatively In-Line
February 27, 2018 4:08 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.95, $0.06 worse than the analyst estimate of $3.01. Revenue for the quarter came in at $436.4 million versus the consensus estimate of $441.31 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2018 EPS of $12.65-$13.25, versus the consensus of $13.07.... More
